Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Average Price Target of $9.40

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.40.

A number of equities research analysts have weighed in on TVRD shares. BTIG Research cut their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, October 12th. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd.

Tvardi Therapeutics Stock Performance

Shares of Tvardi Therapeutics stock opened at $0.97 on Tuesday. The business has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $2.46. Tvardi Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $6.43.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Sell-side analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the second quarter valued at $63,000. BlackRock Inc. bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $181,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $34,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.